Salivary gland tumour

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
ASH, ADC, EMA, Patient, Camptothecin, Research, Therapy, Cancer, Oncogene, Poster, Multiple myeloma, Hematology, PALO, Safety, Therapeutic index, IND, DLBCL, Prednisone, Mantle cell lymphoma, Tumor microenvironment, SMDC, Society, RNA, Venetoclax, Corporation, Spacecraft, SME, Salivary gland tumour, MCL1, Cohort, European Medicines Agency, PDX, B-cell lymphoma, University, HER2, Acute lymphoblastic leukemia, Myelodysplastic syndrome, PTCL, MYC, MCL, Neoplasm, CPT, Peripheral T-cell lymphoma, Small and medium-sized enterprises, CDK9, FDA, RNA polymerase II, NIH, Toxicity, Vaccine, Pharmaceutical industry, Fine chemical, Medical imaging, Rare-earth element, Cryptocurrency

PALO ALTO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “We continue to take a very disciplined approach to our portfolio, focusing our resources on our two lead programs, VIP943 and VIP236.
  • We will present new data on robust preclinical activity at the 65th American Society for Hematology Meeting (ASH 2023) in December.
  • Collaborators from the University of Calgary will present a poster at ASH 2023 showing preclinical activity in pediatric leukemia.
  • For the quarter ended September 30, 2023, Vincerx reported a net loss of approximately $9.7 million, or $0.46 per share, compared to a net loss of approximately $16.9 million, or $0.80 per share, for the quarter ended September 30, 2022.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Retrieved on: 
Monday, October 23, 2023
CR, Memorial Sloan Kettering Cancer Center, PRS, Trastuzumab, Plasma, Cholangiocarcinoma, Aes, ESMO, ISAC, MPH, Nivolumab, Publication, HER2, Congress, LVEF, Salivary gland tumour, European Society for Medical Oncology, MSK, Phenotype, Pharmacodynamics, Bolt, Oncology, SDS, Cancer, Therapy, Patient, Breast, Toxicity, ASCO, TLR, Pharmaceutical industry, Vaccine

BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.

Key Points: 
  • BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.
  • The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab.
  • The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).
  • Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Lymphoma, Salivary gland tumour, Non-small-cell lung cancer, CD19, American Society of Clinical Oncology, CGEM, Breast, G&A, NSCLC, Trial of the century, ASCO, Congress, Phase 1, Endometrial cancer, Patient, Investment, EGFR, TME, Annual general meeting, Financial toxicity, R, Research, FDA, Pembrolizumab, IND, Tumor microenvironment, Society, D, Birth control, Fine chemical, Pharmaceutical industry, Medical imaging, Vaccine, Cullinan

CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • R&D Expenses: Research and development (R&D) expenses were $27.4 million for the second quarter of 2023, compared to $52.1 million for the first quarter of 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $10.2 million for the second quarter of 2023, compared to $10.7 million for the first quarter of 2023.
  • Net Loss: Net loss (before items attributable to noncontrolling interest) for the second quarter of 2023 was $32.2 million, compared with net loss of $58.1 million for the first quarter of 2023.
  • Net losses included the items described above, partially offset by interest income of $5.3 million and $4.5 million in the second quarter and first quarter of 2023, respectively.

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 7, 2023
Myelodysplastic syndrome, AACR, Tumors of the hematopoietic and lymphoid tissues, Salivary gland tumour, Therapy, HER2, DLBCL, Neoplasm, Multiple myeloma, CMC, Control, Cancer, G&A, Research, Burn, SMDC, PDX, Investigational New Drug, Patient, Leukemia, ADC, Spacecraft, R, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Camptothecin, Food, Safety, Pharmaceutical industry, Cryptocurrency

PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • VIP236 is designed to deliver an optimized camptothecin payload to tumors expressing αvβ3, which is found in advanced and metastatic tumors.
  • For the second quarter ended June 30, 2023, Vincerx reported a net loss of approximately $11.2 million, or $0.52 per share.
  • For the second quarter ended June 30, 2022, Vincerx reported a net loss of approximately $18.4 million, or $0.88 per share.
  • For the six-months ended June 30, 2023, Vincerx reported a net loss of $25.5 million, or $1.20 per share, as compared to a net loss of $34.8 million, or $1.66 per share for the same period in 2022.

Global Head and Neck Cancer Therapeutics Market Report 2022: Immunotherapy Against Autoimmune Disorders Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 19, 2022
Pharmaceutical, Health, Oncology, Investment, Oropharyngeal cancer, Lip, Therapy, Squamous cell carcinoma, Research, Laryngeal cancer, Hypopharyngeal cancer, COVID-19, Industry, Salivary gland tumour, Head, Pharmaceutical industry, Retail, Fine chemical

The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.
  • It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues.
  • This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).

Global Salivary Gland Cancer Drugs Market Research Report 2022: Developments by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Monday, May 23, 2022
Pharmaceutical, Health, Oncology, Molecule, Salivary gland tumour, Mall of America, Route of administration, Research, News, Therapy, Key, History, Administration, R, Target, Decision-making, Fine chemical

The "Salivary Gland Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Salivary Gland Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations

Retrieved on: 
Thursday, April 4, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Research, Science, General Health, Chemical compounds, Organic compounds, Aromatic compounds, Tyrosine kinase receptors, Chloroarenes, Aromatic amines, Quinazolines, Epidermal growth factor receptor, Oncogenes, HER2/neu, Salivary gland tumour, Neratinib

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or HER2 mutation.
  • The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer.
  • The Phase II SUMMIT basket trial is an open-label, multi-center, multi-histology, international study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating EGFR, HER2 or HER4 mutations.
  • The expanded HER2-mutant salivary gland cancer cohort and the expanded EGFR exon 18 mutant lung cancer cohort will each now enroll approximately 18 patients.

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

Retrieved on: 
Thursday, August 9, 2018
Cancer, Medicine, Clinical medicine, Antineoplastic drugs, Salivary gland tumour, Pembrolizumab, Salivary gland, Targeted therapy, Cetuximab, Epidermal growth factor receptor, Chemotherapy, Parotid gland

Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.

Key Points: 
  • Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.
  • The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor).
  • Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda.
  • Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.

Adenoid Cystic Carcinoma Pipeline Analysis 2018: Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

Retrieved on: 
Friday, June 1, 2018
Cancer, Adenoid cystic carcinoma, Medicine, Anatomy, Carcinoma, Adenoid, ACC, Ear, Oncology, Ceruminous adenocarcinoma, Salivary gland tumour

The "Adenoid Cystic Carcinoma Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adenoid Cystic Carcinoma Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.
  • Adenoid Cystic Carcinoma Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
  • Adenoid Cystic Carcinoma Pipeline Analysis report covers more than 10 drugs currently in different phases of development.
  • Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma which occurs in the secretory glands, most common ones include the major and minor salivary glands of neck and head.